Division of Abcam PLC
Latest From Epitomics Inc.
Another week has seen another plethora of deals between Chinese domestic players and global gene sequencing firms. Rising demand for individualized treatments and the rush for cancer immuno-therapies is propelling fast growth for the US-Chinese biotech company Crownbio, says its executive chairman Guo-Liang Yu.
BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 2 of 2)
BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.
In a golden age of biotech in China, Crown is transforming from a biologics development service company to a mixed biotech through a planned IPO in Taiwan. Backed by its world-largest patient-derived xenograft models bank, the company is discovering oncology compounds.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Contract Research, Toxicology Testing-CRO
- In Vitro Diagnostics
Laboratory Testing Services
- Anatomical Pathology
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Abcam PLC
- Senior Management
Guo-Liang Yu, PhD, Chmn., Pres. & CEO
Laurie Gee, CFO
- Contact Info
Phone: (650) 583-6688
863 Mitten Rd.
Burlingame, CA 94010-1303
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.